Multiple Myeloma | Specialty

Dr. Schmidt on the Utilization of Bispecific Antibodies in Myeloma

January 22nd 2021

Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in myeloma.

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

January 21st 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

January 20th 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Dr. Kumar on the Emergence of MRD Negativity as an End Point in Multiple Myeloma

January 20th 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Dr. Hari on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

January 19th 2021

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.

Dr. Fonseca on Weighing the Risks With Potential Benefits of Quadruplet Regimens in Myeloma

January 18th 2021

Rafael Fonseca, MD, weighs the risks and benefits of quadruplet regimens in patient with multiple myeloma.

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

x